Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 16/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3333692 | 0.80 | PDE4B (0.47) | PDE4BHRH3HRH1OPRM1 | |
| SCHEMBL3712281 | 0.80 | HRH3 (0.62) | HRH3OPRM1 | |
| SCHEMBL1874992 | 0.78 | HRH3 (0.64) | HRH3HRH1OPRM1 | |
| Hydrochloric Acid SCHEMBL4438262 | 0.77 | HRH3 (0.63) | HRH3HRH1OPRM1 | |
| SCHEMBL3089905 | 0.76 | HRH3 (0.65) | HRH3HRH1 | |
| SCHEMBL1873259 | 0.74 | HRH3 (0.64) | HRH3HRH1 | |
| SCHEMBL6268375 | 0.70 | HRH3 (0.56) | HRH3HRH1 | |
| SCHEMBL3653092 | 0.68 | HRH3 (0.52) | PDE4BHRH3 | |
| SCHEMBL3089908 | 0.67 | PDE4B (0.48) | PDE4BHRH3HRH1OPRM1 | |
| SCHEMBL4363971 | 0.67 | SLC8A1 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207331-B2 | Benzazepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-20100145040-A1 | Benzazepine Derivatives For The Treatment of Neurological Disorders | GLAXO GROUP LIMITED | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145040-A1 | Benzazepine Derivatives For The Treatment of Neurological Disorders | GRIN2C, GRIN2A, GRIN2B | PDE4B 1098/4885HRH3 450/4885HRH1 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.